I love the first line...
YMI - There pipeline is far too long to even try to post. We are talking 30+ clinical trials. Most of these are based on Nimotuzumab, which is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. This company is very global!
They recently raised $17 million dollars, which seems very needed given their vast network of trials. They recently had 2 presentations at the AACR on the Nimo drug(Source).
They have several presentations at ASCO. There could be more than what is below, it is just hard to find these. After a little digging, we have:
"#5530: An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study.
#5565: Results from a pilot study of nimotuzumab with concurrent chemoradiation in patients with locally advanced squamous cell carcinoma of head and neck."
Posted by Patrick at 10:52 PM
Labels: AEZS, CYCC, SNSS, YMI
Market Data 
Markets 
AI
